Skip to main content
. Author manuscript; available in PMC: 2018 Jan 15.
Published in final edited form as: J Control Release. 2015 Nov 11;240:93–108. doi: 10.1016/j.jconrel.2015.11.010

Table 1.

Elastin-like polypeptide (ELP) nanomedicines under commercial investigation.

Product/Agent Indications Status Company References
siEVI1-ELP Various cancers (breast, ovarian, pancreatic, and lung) Preclinical PeptiMed [139]
Liposome-ELP conjugates Breast cancer Preclinical Samsung [98]
VIP-ELP (Vasomera™) Pulmonary arterial hypertension, cardiomyopathies, cystic fibrosis Phase I PhaseBio [130-133, 140, 141]
GLP1-ELP (Glymera™) Type II diabetes Phase IIB PhaseBio [61, 91, 138]